Loading…
← CockpitCompetitor Analysis › 1875.HK BioDlink International Company LimitedOpen in the cockpit ↗

BioDlink International Company Limited1875.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Major
Momentum neutral 46
Mkt cap
$334M
US dollars, full cap
Free float
14%
of shares outstanding
$/day
$182,255
20-day average traded
Fwd P/E
288.2×
forward earnings
ROIC−WACC
-23.6 pp
WACC 5.5%
Hurdle
n/a
no reverse DCF
Next earnings
127 days
25 Mar 2027
Close · HKDHK$3.36
1D+0.3%
1W-0.9%
1M-2.0%
3M-14.1%
6M-23.8%
YTD+34.4%
1Y+56.3%
ATR %5.3%
52w lowhigh42.8% off high

What BioDlink International does

Employees: 613

BioDlink International at a glance

Size BioDlink International (1875.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $334M, the 857th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$3.36 on 18 Nov 2026.

Performance Over six months the shares fell 23.8%, against -14.2% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 7th lowest of 21 in its peer set.

Growth Revenue fell 51.1% over the last twelve months (peer median +3.0%); the operating margin is -31.2% (peer median 3.0%).

Valuation It trades at 288.2× forward earnings against a peer median of 20.7× (most expensive of 6).

Capital Return on invested capital runs 23.6 points below its cost of capital (5.5% WACC).

Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026Peer median 851875.HK 77
Six months, rebased to 100: BioDlink International against the median of its 20 peers (local-currency closes).

BioDlink International financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$563MHK$811MHK$1.19BHK$863MHK$514M
Revenue growth—-32%+38%+68%—
Gross profitHK$95.1MHK$403MHK$831MHK$608MHK$402M
EBITDA-HK$86.3M-HK$25.4MHK$88.0M-HK$994,500-HK$11.7M
Net income-HK$181M-HK$109MHK$37.7M-HK$41.7M-HK$58.0M
Free cash flown/a-HK$51.9M-HK$22.3M-HK$170M-HK$216M
Capital expenditureHK$10.1MHK$46.7MHK$134MHK$225MHK$279M
Total debtn/aHK$427MHK$421MHK$381MHK$325M

Quarterly statements and history in the cockpit →

BioDlink International competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%0%+25%+50%SOLARAMYX3015091720002168SECARE005250AVIR368AINO4886INDSWFTLAB4569UNICHEMLABALEMBICLTD1875.HK6-month return →1-month return →
Up and to the right = strong over both horizons. BioDlink International is the large dot.

Fundamentals: revenue growth against valuation

-40%-20%0%+20%0×100×200×300×SOLARASECARE368A488645691875.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. BioDlink International is the large dot.

BioDlink International competitors and peer comparison

How BioDlink International compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

BioDlink International against its 20 peers (data as of 18 Nov 2026)
Measure1875.HKPeer medianRank in peer set
1-month return-2.0%-6.4%7th highest of 21
6-month return-23.8%-14.2%7th lowest of 21
Distance from 52-week high-42.8%-32.2%6th lowest of 21
Revenue growth (TTM)-51.1%+3.0%lowest of 20
Operating margin-31.2%3.0%4th lowest of 19
Forward P/E288.2×20.7×most expensive of 6
ROIC minus cost of capital-23.6 pp-7.1 pp2nd lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
BioDlink International 1875.HKHong Kong$334M-24%-51%-31%288.2×n/an/a
Solara Active Pharma Sciences SOLARA.NSIndia$334M+12%+27%8%20.7×38.3%-3.2%
Mayne Pharma MYX.AXAustralia$333M+155%-6%-14%n/a19.0%-0.9%
Kingchem (Liaoning) Life Science 301509.SZChina$333M-28%+3%6%n/a9.2%+6.5%
Standard Chemical & Pharmaceutical 1720.TWTaiwan$329M-1%+5%22%n/a-11.5%+10.3%
Chongqing Hifuture Information Technology 002168.SZChina$326M-27%+2%-6%n/a14.3%-14.0%
Beihai Gofar Chuanshan Biological 600538.SSChina$326M-39%+10%-8%n/an/an/a
Foresee Pharmaceuticals 6576.TWOTaiwan$322M-12%+6%-104%n/an/an/a
Swedencare SECARE.STSweden$321M-24%+3%7%24.9×6.1%+62.1%
GC Corp. 005250.KSSouth Korea$321M-45%+2%3%n/an/an/a
Atea Pharmaceuticals AVIRUnited States$320M-5%n/an/an/an/an/a
Guizhou Yibai Pharmaceutical 600594.SSChina$351M-23%-26%-15%n/a8.0%-11.3%
Kitazato 368A.TJapan$317M+7%+9%52%12.2×-16.8%+5.4%
Inovio Pharmaceuticals INOUnited States$317M+37%+64%-25,954%n/an/an/a
ASKA Pharmaceutical 4886.TJapan$354M-24%+11%n/a12.9×n/an/a
Ind-Swift Laboratories INDSWFTLAB.NSIndia$314M+150%+66%9%n/an/an/a
Anhui Fengyuan Pharmaceutical 000153.SZChina$355M-17%-24%3%n/a3.6%+3.1%
Chengdu Huasun Technology 000790.SZChina$312M-20%-36%-57%n/a27.5%-6.4%
KYORIN Pharmaceutical 4569.TJapan$360M-22%-6%2%35.5×6.7%+4.2%
Unichem Laboratories UNICHEMLAB.NSIndia$361M+28%+6%5%n/an/an/a
Alembic ALEMBICLTD.NSIndia$309M+25%-5%26%n/a44.3%+26.7%

Questions

Which companies are BioDlink International's closest peers?
The cockpit's peer set: Solara Active Pharma Sciences (SOLARA.NS), Mayne Pharma (MYX.AX), Kingchem (Liaoning) Life Science (301509.SZ), Standard Chemical & Pharmaceutical (1720.TW), Chongqing Hifuture Information Technology (002168.SZ), Beihai Gofar Chuanshan Biological (600538.SS), Foresee Pharmaceuticals (6576.TWO), Swedencare (SECARE.ST).
Is BioDlink International expensive compared with its peers?
On forward p/e it trades at 288.2× against a peer median of 20.7×, most expensive of 6 in its peer set.
How has BioDlink International stock performed?
Over six months to 18 Nov 2026 the shares returned -23.8% against -14.2% for the median peer; over one year +56.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.